Logo Logo
Switch Language to German
Arver, S.; Stief, C.; Rosette, J. de la; Jones, T. H.; Neijber, A.; Carrara, D. (2018): A new 2% testosterone gel formulation: a comparison with currently available topical preparations. In: Andrology, Vol. 6, No. 3: pp. 396-407
Full text not available from 'Open Access LMU'.


Testosterone gel formulations have become a popular testosterone replacement therapy in patients with hypogonadism since their advent in the year 2000. The gel formulations restore testosterone levels to mid-normal physiological levels (14-17.5nmol/L) as early as within 24h, and help alleviate the signs and symptoms of testosterone deficiency, thereby leading to an improved quality of life. Although testosterone gels have a favourable efficacy and safety profile as compared to injectable and patch formulations, risk of secondary exposure poses a challenge. Approved testosterone topical formulations include Tostrex((R)) (Tostran((R)), Fortesta((R))), Androgel((R)) (Testogel((R))), Testim((R)) and Axiron((R)) (solution), which have a favourable efficacy profile and positively impacted patient-reported outcome(s). Besides, Testavan, which is a 2% testosterone gel, is under registration in Europe and already approved in Australia in May 2017. Testavan uses a novel hydroalcoholic and highly viscous topical formulation. This product comes with a metered dose dispenser and a cap applicator that allows a hands-free application for precise dispensing and application. The present article provides a comprehensive review of pharmacokinetic, tolerability and safety profile of the testosterone gels available in the marketalong with the new 2% testosterone gel, Testavan.